Company news
Oncolys BioPharma, Inc. news in 2022
Oncolys BioPharma, Inc.'s news releases, calls and decks from 2022, newest first.
Non-consolidated Financial Results for the Nine Months Ended September 30, 2022
November 4, 2022
Announcement of Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Progressive Supranuclear Pals
August 17, 2022
Non-consolidated Financial Results for the Six Months Ended June 30, 2022
August 5, 2022
Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2021
February 10, 2022
Announcement of Enrollment of First Patient in Phase IIa study for OBP-601 (Censavudine, TPN-101) in patients with ALS and/or FTD
January 21, 2022